Long-term follow-up of patients with hairy cell leukemia after cladribine treatment

Blood

Volumn 92, Issue 6, 1998, Pages 1918-1926

  Saven, Alan ^a   Burian, Carol ^b   Koziol, James A ^b   Piro, Lawrence D ^b  

^a SCRIPPS CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; INTERFERON; PENTOSTATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; SECOND CANCER; SPLENECTOMY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032530684     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.6.1918.418k33_1918_1926     Document Type: Article

References (33)

1. Bouroncle BA, Wiseman BK, Doan CA: Leukemic reticuloendotheliosis. Blood 13:609, 1958
2. Golomb HM, Catovsky D, Golde DW: Hairy cell leukemia: A clinical review of 71 cases. Ann Intern Med 89:677, 1978
3. Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WEN, Cassileth PA, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson BD. Randomized comparison of pentostatin versus Interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 13:974, 1995
4. Tallman MS, Hakimian D, Rademaker AW, Zanzig C, Wollins E, Rose E, Peterson LC: Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: Long-term follow-up of the Northwestern University experience. Blood 88:1954, 1996
5. Saven A, Piro L: Newer purine analogues for treatment of hairy cell leukemia. N Engl J Med 330:691, 1994
6. Piro LD, Carrera CJ, Carson DA, Beutler E: Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117, 1990
7. Estey EM, Kurzrock R, Kantarjian HM, O'Brien S, McCredie K, Beran M, Koller C, Keating M, Hirsch-Ginsberg C, Huy YO, Stass S, Freireich E: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79:882, 1992
8. Juliusson G, Liliemark J: Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): Relation to opportunistic infections. Blood 79:888, 1992
9. Tallrnan MS, Hakimian D, Variakojis D, Koslow D, Sisney GA, Rademaker AW, Rose E, Kaul K: A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 9:2203, 1992
10. Saven A, Ellison D, Piro LD: The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 14:121, 1994fsuppl 1)
11. Saven A, Kantor RA, Kosty M, Koziol JA, Piro LD: Randomized trial of pentoxifylline for 2-chlorodeoxyadenosine (2-CdA)-induced neutropenic fever in hairy cell leukemia (HCL) patients. Proc Am Soc Clin Oncol 13:1029, 1994 (abstr)
12. Beutler E: Cladribine (2-chlorodeoxyadenosine). Lancet 340:952, 1992
13. Hakimian D, Tallman MS, Hogan DK, Rademaker AW, Rose E, Nemcek AA Jr: Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemia. J Clin Oncol 12:268, 1994
14. Oken MM, Creech LH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649, 1982
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457, 1958
16. Cox DR: Regression models and life tables. J Roy Statist Soc Ser 34:187, 1972
17. Review, 1973-1991: Tables and graphs, National Cancer Institute. National Institute of Health Publication number 94-2789. Bethesda. MD, 1994
18. Ellison DJ, Sharpe RW, Robbins BA. Spinosa JC, Leopard JD, Saven A, Piro LD: Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 84:4310, 1994
19. Juliusson G, Lenkei R, Liliemark J: Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: Phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 83:3672, 1994
20. + lymphocyte counts in patients with hairy cell leukemia. Blood 83:2906, 1994
21. Hoffman MA. Janson D, Rose E, Rai KR: Treatment of hairy celt leukemia with cladribine: Response, toxicity and long-term follow-up. J Clin Oncol 15:1138, 1997
22. Kraut EH, Grever MR, Bouroncle BA: Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 84:4061, 1994
23. Hakimian D, Tallman MS, Kiley C, Peterson LA: Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 82:1798, 1993
24. Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doven C, Mineur P, Glorieux P, Driesschaert P, Sokal G, Martial P, Michaux JL: A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell patients in complete remission. Leukemia 8:1153, 1994
25. Saven A, Piro LD: Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2′-deoxycoformycin. Ann Intern Med 119:278, 1993
26. Seymour JF, Estey EH, Keating MJ, Kurzrock R: Response to interferon-α in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 9:929, 1995
27. Carrera CJ, Piro LD, Saven A, Cox K, Beutler E, Carson DA, Kipps TJ: Restoration of lymphocyte subsets following 2-chlorodeoxyadenosine remission induction in hairy cell leukemia. Blood 76:260a, 1990 (abstr, suppl)
28. Chunduru SK, Blakley RL: Effect of 2′-chlorodeoxyadenosine triphosphate on nucleotide incorporation rate of human polymerase a and β. Proc Am Assoc Cancer Res 97:17, 1991 (abstr)
29. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA: Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75:377, 1985
30. Seto S, Carrera CJ, Wasson DB, Carson DA: Inhibition of DMA repair by deoxyadenosine in resting human lymphocytes. J Immunol 136:2839, 1986
31. Kurzrock R, Strom SS, Estey E, O'Brien S, Keating MJ, Jiang H, Adams T, Talpaz M: Second cancer risk in hairy cell leukemia: Analysis of 350 patients. J Clin Oncol 15:1803, 1997
32. Cheson BD, Vena D, Freidlin B, Barren J, Sorensen JM: The risk of secondary malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Proc Am Soc Clin Oncol 16:52, 1997 (abstr)
33. Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman JW: Increased incidence of second neoplasms in patients treated with interferon α-2b for hairy cell leukemia: A clinicopathologic assessment. Blood 83:2931, 1994